2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07D.07 Assessing the Adoption of Combined Immunotherapy and Chemotherapy in Eligible Patients with Non-Small Cell Lung Cancer

EP.07D.07 Assessing the Adoption of Combined Immunotherapy and Chemotherapy in Eligible Patients with Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study conducted by Fatemehsadat Pezeshkian and co-authors at Brigham and Women’s Hospital examined the adoption of combined immunotherapy and chemotherapy in treating eligible patients with non-small cell lung cancer (NSCLC) following FDA approval in March 2022. This approach, termed neoadjuvant chemoimmunotherapy, involves the use of immune checkpoint inhibitors before surgical intervention. Phase III trials have demonstrated favorable outcomes for patients with resectable NSCLC, leading to its recommendation as standard care in international guidelines.<br /><br />Key findings from their assessment at the hospital include:<br /><br />- Patients undergoing neoadjuvant therapy were generally younger than those opting for upfront surgery (66 years vs. 72 years).<br />- While primary tumor size did not significantly vary between groups, patients with cN1-2 disease were more likely to receive neoadjuvant treatment compared to those with tumors less than 4 cm and no lymph node involvement.<br />- Invasive mediastinal staging and mutational testing were more prevalent among those receiving neoadjuvant therapy.<br />- Use of neoadjuvant chemoimmunotherapy increased by 6% each quarter during the study period, while the use of traditional neoadjuvant chemotherapy/-radiation and upfront surgery declined.<br />- Factors such as increasing age, tumor size, nodal involvement, and duration of the study correlated with the use of neoadjuvant treatment.<br /><br />Overall, the hospital observed a significant uptick in the employment of neoadjuvant chemoimmunotherapy, especially in patients with lymph node metastasis and larger tumors, since June 2022. The findings underscore the need for multidisciplinary approaches and suggest that further real-world data could enhance decision-making and treatment strategies in NSCLC.

Asset Subtitle

Fatemehsadat Pezeshkian

Meta Tag

Speaker Fatemehsadat Pezeshkian

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

neoadjuvant chemoimmunotherapy

non-small cell lung cancer

NSCLC

immunotherapy

chemotherapy

immune checkpoint inhibitors

FDA approval

Brigham and Women’s Hospital

lymph node metastasis

multidisciplinary approaches